Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)Completed
NCT04210115Phase 3Updated Jul 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC) · Gastroesophageal Junction Carcinoma (GEJC) · Esophageal Adenocarcinoma (EAC)
United States, Argentina, Belgium, Brazil, Canada +22 more
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)Completed
NCT05013905Phase 2Updated Jul 22, 2026
Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Crohn Disease
United States, Australia, Belgium, Canada, Czechia +3 more
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)Active Not Recruiting
NCT06814145Phase 2Updated Jul 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Hypertension, Pulmonary
United States, Belgium, Canada, France, Germany +7 more
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasActive Not Recruiting
NCT03179930Phase 2Updated Jul 22, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Lymphoma · Relapsed · Refractory
United States
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Recruiting
NCT04879329Phase 2Updated Jul 22, 2026
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Urothelial Carcinoma
United States, Argentina, Australia, Belgium, Canada +7 more
Pembrolizumab In Central Nervous System MetastasesActive Not Recruiting
NCT02886585Phase 2Updated Jul 21, 2026
Sponsor: Massachusetts General Hospital
Brain Metastases
United States
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other CancersRecruiting
NCT05098132Phase 1, Phase 2Updated Jul 21, 2026
Sponsor: Synthekine
Advanced Solid Tumor · Non Small Cell Lung Cancer · Untreated Advanced NSCLC · 1st Line NSCLC
United States, Georgia, Ireland, Spain
Palbociclib and Pembrolizumab In Central Nervous System MetastasesRecruiting
NCT02896335Phase 2Updated Jul 21, 2026
Sponsor: Massachusetts General Hospital
Metastatic Malignant Neoplasm to Brain · Recurrent Brain Metastases · Progressive Brain Metastases
United States
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian CancerActive Not Recruiting
NCT05467670Phase 2Updated Jul 21, 2026
Sponsor: Alexander B Olawaiye, MD
Ovarian Cancer
United States
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruiting
NCT06899126Phase 3Updated Jul 21, 2026
Sponsor: Daiichi Sankyo
Non-small Cell Lung Cancer
United States, Argentina, Belgium, Brazil, Chile +18 more
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)Active Not Recruiting
NCT06698042Phase 3Updated Jul 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Cancer · Non-Small Cell Lung Cancer
United States, China, Germany, Guatemala, Japan +7 more
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active Not Recruiting
NCT05540327Phase 2Updated Jul 20, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
United States, Argentina, Australia, Brazil, Bulgaria +17 more
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)Recruiting
NCT06380738N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
Germany
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Active Not Recruiting
NCT06456346Phase 3Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Essential Thrombocythemia
United States, Argentina, Australia, Austria, Canada +18 more
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)Recruiting
NCT07222488Phase 1, Phase 2Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer · Urinary Bladder Neoplasms
United States, Austria, Belgium, Canada, France +7 more
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]Active Not Recruiting
NCT03504163Phase 2Updated Jul 17, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Bladder Cancer
United States
A Study of V132 in Healthy Older Participants (V132-001)Not Yet Recruiting
NCT07712575Phase 1Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)Recruiting
NCT06941272Phase 1, Phase 2Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Australia, Belgium, Brazil, Canada +18 more
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive Not Recruiting
NCT03069378Phase 2Updated Jul 17, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Sarcoma · Epithelioid Sarcoma · Cutaneous Angiosarcoma
United States
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)Recruiting
NCT07030712Phase 1Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Neoplasm
United States, Israel, Netherlands
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)Recruiting
NCT06979596Phase 2Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Argentina, Brazil, Canada, Chile +8 more
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerActive Not Recruiting
NCT04619004Phase 2Updated Jul 17, 2026
Sponsor: Daiichi Sankyo
Non-Small Cell Lung Cancer Metastatic · Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
United States, Australia, Austria, Belgium, Bulgaria +11 more
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)Active Not Recruiting
NCT04808999Phase 2Updated Jul 16, 2026
Sponsor: Diwakar Davar
Squamous Cell Carcinoma
United States
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)Recruiting
NCT06004336Phase 2Updated Jul 16, 2026
Sponsor: M.D. Anderson Cancer Center
Oligometastatic Renal Cell Carcinoma
United States
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)Recruiting
NCT07049926Phase 1, Phase 2Updated Jul 16, 2026
Sponsor: Merck Sharp & Dohme LLC
Renal Cell Carcinoma
United States, Chile, France, Israel, Poland +3 more

Previous page Next page